• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

我们理解未满足的需求吗?一项关于使用寿命等效长度(LOLE)作为以患者为中心的未满足需求衡量指标的提议。

Do We Understand Unmet Need? A Proposal to Use Length-Of-Life Equivalent (LOLE) as a Patient-Centric Measure of Unmet Need.

作者信息

Marsh Kevin, Reynolds Robert F, Nelsen Linda, Watt Stephen, Escontrías Omar A, Hauber Brett

机构信息

Evidera, London, UK.

GSK, New York, NY, USA.

出版信息

Pharmacoecon Open. 2025 May;9(3):341-350. doi: 10.1007/s41669-025-00560-8. Epub 2025 Feb 17.

DOI:10.1007/s41669-025-00560-8
PMID:39961985
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12037453/
Abstract

Many decision-makers have emphasized the importance of leveraging patient experience data to measure unmet need. However, there is no standardized, patient-centric unmet need measure that formalizes how the value judgements inherent in such a measure should be made. Several initiatives have identified measuring unmet need as one of the primary uses of patient preference data. After reviewing how decision-makers define unmet need, this paper proposes that a thresholding method could be used to generate a standardized, patient-centric, disease-agnostic, quantitative unmet need estimate, length of life equivalent (LOLE). LOLE would address some of the limitations of current methods, including facilitating capture of the impact of disease beyond health-related quality of life, and being more sensitive to the impact of a disease on patients. However, the acceptability of LOLE raises questions for decision-makers, including: Is length of life equivalence the best common metric in which to express unmet need? Is it appropriate to rate a disease as having no unmet need if patients are unwilling to trade off life expectancy for improvements in their quality of life? Can LOLE be estimated for more complex disease profiles? Is thresholding the appropriate method to use to estimate LOLE? How should LOLE be integrated into decision-making, including the level of LOLE that defines different levels of unmet need? Further work could usefully address these questions with decision-makers.

摘要

许多决策者都强调了利用患者体验数据来衡量未满足需求的重要性。然而,目前尚无标准化的、以患者为中心的未满足需求衡量方法,来规范此类衡量中固有价值判断的形成方式。多项举措已将衡量未满足需求确定为患者偏好数据的主要用途之一。在审视了决策者如何定义未满足需求之后,本文提出可以使用一种阈值方法来生成标准化的、以患者为中心的、与疾病无关的定量未满足需求估计值——等效生命长度(LOLE)。LOLE将解决当前方法的一些局限性,包括便于捕捉疾病对健康相关生活质量之外的影响,以及对疾病对患者的影响更为敏感。然而,LOLE的可接受性给决策者带来了一些问题,包括:等效生命长度是否是表达未满足需求的最佳通用指标?如果患者不愿意为了改善生活质量而牺牲预期寿命,将一种疾病评定为不存在未满足需求是否合适?对于更复杂的疾病情况,能否估计LOLE?阈值法是否是估计LOLE的合适方法?LOLE应如何纳入决策过程,包括定义不同未满足需求水平的LOLE水平?进一步的工作可以有效地与决策者一起解决这些问题。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef64/12037453/2da0422b61ea/41669_2025_560_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef64/12037453/4a0ac2333e6c/41669_2025_560_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef64/12037453/2da0422b61ea/41669_2025_560_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef64/12037453/4a0ac2333e6c/41669_2025_560_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef64/12037453/2da0422b61ea/41669_2025_560_Fig2_HTML.jpg

相似文献

1
Do We Understand Unmet Need? A Proposal to Use Length-Of-Life Equivalent (LOLE) as a Patient-Centric Measure of Unmet Need.我们理解未满足的需求吗?一项关于使用寿命等效长度(LOLE)作为以患者为中心的未满足需求衡量指标的提议。
Pharmacoecon Open. 2025 May;9(3):341-350. doi: 10.1007/s41669-025-00560-8. Epub 2025 Feb 17.
2
Does minimum follow-up time post-diagnosis matter? An assessment of changing loss of life expectancy for people with cancer in Western Australia from 1982 to 2016.诊断后最短随访时间是否重要?1982 年至 2016 年澳大利亚西部癌症患者预期寿命损失变化的评估。
Cancer Epidemiol. 2020 Jun;66:101705. doi: 10.1016/j.canep.2020.101705. Epub 2020 Mar 27.
3
Number of life-years lost at the time of diagnosis and several years post-diagnosis in patients with solid malignancies: a population-based study in the Netherlands, 1989-2019.实体恶性肿瘤患者诊断时及诊断后数年的生命年损失数:1989 - 2019年荷兰的一项基于人群的研究
EClinicalMedicine. 2023 May 11;60:101994. doi: 10.1016/j.eclinm.2023.101994. eCollection 2023 Jun.
4
Impact of cancer diagnosis on life expectancy by area-level socioeconomic groups in New South Wales, Australia: a population-based study.澳大利亚新南威尔士州按地区社会经济群体划分的癌症诊断对预期寿命的影响:一项基于人群的研究。
Cancer Biol Med. 2024 Jul 22;21(8):692-702. doi: 10.20892/j.issn.2095-3941.2024.0166.
5
Temporal trends in loss of life expectancy after a cancer diagnosis among the Australian population.澳大利亚人群癌症诊断后预期寿命损失的时间趋势。
Cancer Epidemiol. 2020 Apr;65:101686. doi: 10.1016/j.canep.2020.101686. Epub 2020 Feb 13.
6
Excess Mortality and Loss of Life Expectancy After Myocardial Infarction: A Registry-Based Matched Cohort Study.心肌梗死后的超额死亡率和预期寿命损失:一项基于登记处的匹配队列研究。
Circulation. 2024 Sep 10;150(11):826-835. doi: 10.1161/CIRCULATIONAHA.124.068739. Epub 2024 Jul 5.
7
Heart failure patients' perspectives on treatment outcomes and unmet medical needs: A qualitative preference study.心力衰竭患者对治疗结果和未满足医疗需求的看法:一项定性偏好研究。
ESC Heart Fail. 2024 Oct;11(5):3075-3084. doi: 10.1002/ehf2.14891. Epub 2024 Jun 10.
8
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
9
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
10
Antiviral Effects of Leaf Extract on Murine Norovirus-1 (MNV-1), a Human Norovirus Surrogate, and Potential Application to Model Foods.叶提取物对人诺如病毒替代物小鼠诺如病毒-1(MNV-1)的抗病毒作用及其在模拟食品中的潜在应用。
Antibiotics (Basel). 2020 Oct 14;9(10):697. doi: 10.3390/antibiotics9100697.

本文引用的文献

1
Identification of health-related needs: The needs examination, evaluation and dissemination (NEED) assessment framework.确定与健康相关的需求:需求检查、评估与传播(NEED)评估框架。
Health Policy. 2025 May;155:105263. doi: 10.1016/j.healthpol.2025.105263. Epub 2025 Feb 13.
2
Multidimensional Thresholding for Individual-Level Preference Elicitation.多维阈限法在个体水平偏好 elicitation 中的应用。
Value Health. 2024 Jun;27(6):737-745. doi: 10.1016/j.jval.2024.02.009. Epub 2024 Feb 28.
3
A systematic literature review of disability weights measurement studies: evolution of methodological choices.
残疾权重测量研究的系统文献综述:方法选择的演变
Arch Public Health. 2022 Mar 24;80(1):91. doi: 10.1186/s13690-022-00860-z.
4
Towards a New Understanding of Unmet Medical Need.迈向对未满足医疗需求的新理解。
Appl Health Econ Health Policy. 2021 Nov;19(6):785-788. doi: 10.1007/s40258-021-00655-3. Epub 2021 Jun 18.
5
Evaluating the Consistency of Patient Preference Estimates: Systematic Variation in Survival-Adverse Event Trade-Offs in Patients with Cancer or Cardiovascular Disease.评估患者偏好估计的一致性:癌症或心血管疾病患者生存-不良事件权衡的系统差异。
Patient. 2022 Jan;15(1):69-75. doi: 10.1007/s40271-021-00513-3. Epub 2021 May 31.
6
Sustaining Meaningful Patient Engagement Across the Lifecycle of Medicines: A Roadmap for Action.贯穿药品全生命周期的有意义的患者参与:行动路线图。
Ther Innov Regul Sci. 2021 Sep;55(5):936-953. doi: 10.1007/s43441-021-00282-z. Epub 2021 May 10.
7
Patient and public involvement in health technology assessment: update of a systematic review of international experiences.患者和公众参与卫生技术评估:国际经验系统评价更新。
Int J Technol Assess Health Care. 2021 Feb 5;37:e36. doi: 10.1017/S0266462321000064.
8
Modifying NICE's Approach to Equity Weighting.修改 NICE 的公平加权方法。
Pharmacoeconomics. 2021 Feb;39(2):147-160. doi: 10.1007/s40273-020-00988-2. Epub 2021 Jan 31.
9
Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.204 个国家和地区 1990-2019 年 369 种疾病和伤害导致的全球负担:2019 年全球疾病负担研究的系统分析。
Lancet. 2020 Oct 17;396(10258):1204-1222. doi: 10.1016/S0140-6736(20)30925-9.
10
Use of Patient Preferences in Health Technology Assessment: Perspectives of Canadian, Belgian and German HTA Representatives.使用患者偏好进行卫生技术评估:加拿大、比利时和德国 HTA 代表的观点。
Patient. 2021 Jan;14(1):119-128. doi: 10.1007/s40271-020-00449-0.